We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+31.14%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.52B
AUM Growth
+$340M
Cap. Flow
+$116M
Cap. Flow %
7.63%
Top 10 Hldgs %
75.66%
Holding
47
New
7
Increased
11
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$78.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$58M
3
BPMC
Blueprint Medicines
BPMC
+$35.3M
4
EXAS
Exact Sciences
EXAS
+$21.3M
5
NTLA icon
Intellia Therapeutics
NTLA
+$18.3M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$29.9M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$25.6M
3
MXCT icon
MaxCyte
MXCT
+$18M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$17.4M
5
DNLI icon
Denali Therapeutics
DNLI
+$16.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARVN icon
26
Arvinas
ARVN
$520M
$8.9M 0.58%
+200,000
New +$9.71M
MRTX
27
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.98M 0.46%
+100,000
New +$7.4M
CLDX icon
28
Celldex Therapeutics
CLDX
$2.96B
$4.64M 0.3%
165,000
– –
GLUE icon
29
Monte Rosa Therapeutics
GLUE
$1.3B
$4.17M 0.27%
510,882
– –
MRNA icon
30
Moderna
MRNA
$21.9B
$3.84M 0.25%
+32,500
New +$4.93M
OMIC
31
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$3.36M 0.22%
44,857
+16,000
+55% +$1.67M
NVTA
32
DELISTED
Invitae Corporation
NVTA
$2.77M 0.18%
1,125,888
+87,500
+8% +$266K
CERE
33
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$2.26M 0.15%
+80,000
New +$2.38M
EXAI
34
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$1.76M 0.12%
213,900
-450,000
-68% -$4.54M
DNTH icon
35
Dianthus Therapeutics
DNTH
$5.8B
$451K 0.03%
20,000
-130,938
-87% -$3.58M
KRON
36
DELISTED
Kronos Bio
KRON
$415K 0.03%
123,839
– –
LIAN
37
DELISTED
LianBio American Depositary Shares
LIAN
$411K 0.03%
206,415
– –
AGIO icon
38
Agios Pharmaceuticals
AGIO
$1.82B
– –
-785,000
Closed -$17.4M
FDMT icon
39
4D Molecular Therapeutics
FDMT
$527M
– –
-555,455
Closed -$3.88M
GH icon
40
Guardant Health
GH
$21.3B
– –
-272,500
Closed -$11M
ORIC icon
41
Oric Pharmaceuticals
ORIC
$1.1B
– –
-601,515
Closed -$2.69M
PMVP icon
42
PMV Pharmaceuticals
PMVP
$59.7M
– –
-300,000
Closed -$4.28M
SGMO
43
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-1,000,000
Closed -$4.14M
TNGX icon
44
Tango Therapeutics
TNGX
$4.43B
– –
-3,500,000
Closed -$15.9M
KRTX
45
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-85,000
Closed -$10.8M
SNCE
46
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
– –
-11,250
Closed -$452K
GBT
47
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-800,000
Closed -$25.6M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Casdin Capital held 47 positions worth $1.52B, up 29% from $1.18B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Casdin Capital deployed $116M of net new capital in Q3 2022, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Illumina: 395,780 shares worth $73.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $29.9M trimmed.

  • Casdin Capital's largest Q3 2022 buy was Illumina: 395,780 shares worth $73.5M.
  • Casdin Capital added most to Sarepta Therapeutics in Q3 2022, an estimated $58M increase.
  • Casdin Capital's biggest Q3 2022 reduction was Alnylam Pharmaceuticals, cutting an estimated $29.9M.
  • Casdin Capital fully exited Global Blood Therapeutics, Inc. in Q3 2022, selling an estimated $25.6M.
  • Casdin Capital's ten largest holdings make up 76% of its $1.52B portfolio in Q3 2022.
  • Casdin Capital opened 7 new positions and closed 10 in Q3 2022.
  • Casdin Capital's portfolio value rose 29% quarter-over-quarter to $1.52B.

Based on Casdin Capital's 13F filing for Q3 2022, filed 14 Nov 2022.